Theranostics of Primary Prostate Cancer: beyond PSMA and GRP-R - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Cancers Année : 2023

Theranostics of Primary Prostate Cancer: beyond PSMA and GRP-R

Résumé

The imaging of Prostate-Specific Membrane Antigen (PSMA) is now widely used at the initial staging of prostate cancers in patients with a high metastatic risk. However, its ability to detect low-grade tumor lesions is not optimal. Methods: First, we prospectively performed neurotensin receptor-1 (NTS1) IHC in a series of patients receiving both [68Ga]Ga-PSMA-617 and [68Ga]Ga-RM2 before prostatectomy. In this series, PSMA and GRP-R IHC were also available (n = 16). Next, we aimed at confirming the PSMA/GRP-R/NTS1 expression profile by retrospective autoradiography (n = 46) using a specific radiopharmaceuticals study and also aimed to decipher the expression of less-investigated targets such as NTS2, SST2 and CXCR4. Results: In the IHC study, all samples with negative PSMA staining (two patients with ISUP 2 and one with ISUP 3) were strongly positive for NTS1 staining. No samples were negative for all three stains—for PSMA, GRP-R or NTS1. In the autoradiography study, binding of [111In]In-PSMA-617 was high in all ISUP groups. However, some samples did not bind or bound weakly to [111In]In-PSMA-617 (9%). In these cases, binding of [111n]In-JMV 6659 and [111In]In-JMV 7488 towards NTS1 and NTS2 was high. Conclusions: Targeting PSMA and NTS1/NTS2 could allow for the detection of all intraprostatic lesions.

Domaines

Cancer Chimie
Fichier principal
Vignette du fichier
2023_Cancers-15,2345-2360.pdf (4.99 Mo) Télécharger le fichier
Origine Publication financée par une institution
Licence

Dates et versions

hal-04075693 , version 1 (20-04-2023)

Licence

Identifiants

Citer

Romain Schollhammer, Marie-Laure Quintyn Ranty, Henri de Clermont Gallerande, Florine Cavelier, Ibai E Valverde, et al.. Theranostics of Primary Prostate Cancer: beyond PSMA and GRP-R. Cancers, 2023, 15 (8), pp.2345. ⟨10.3390/cancers15082345⟩. ⟨hal-04075693⟩
16 Consultations
14 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More